SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithKline Pharma reports 14% rise in Q2 net profit

11 Aug 2011 Evaluate

GlaxoSmithKline Pharmaceuticals has reported unaudited results for the second quarter ended June 30, 2011.

The company’s net profit for the quarter ended June 30, 2011 rose by 14.38% at Rs 147.54 crore as compared to Rs 128.99 crore for the corresponding quarter last year. Its total income increased 13.07% at Rs 573.85 crore for the quarter under review from Rs 507.51 crore for the same quarter last year.

GlaxoSmithKline Pharmaceuticals, is one oldest pharmaceutical company in India. Internationally it has created many brands such as Ribena, Horlicks, Lucozade, Aquafresh, Sensodyne, Panadol, Tums and Zovirax, among others.

Glaxosmithkline Phar Share Price

2419.10 12.85 (0.53%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×